# Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

> **NCT05953337** · NA · ACTIVE_NOT_RECRUITING · sponsor: **ABK Biomedical** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatocellular Carcinoma Non-resectable
- Liver Cancer

## Interventions

- **DEVICE:** EYE90 Microspheres Treatment

## Key facts

- **NCT ID:** NCT05953337
- **Lead sponsor:** ABK Biomedical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953337, "Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05953337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*